Corporate ActionMay 21, 2026, 09:01 AM
Cue Biopharma Seeks Shareholder Approval for Warrant Issuance, Stock Plan
AI Summary
Cue Biopharma, Inc. is holding a Special Meeting of Stockholders on June 1, 2026, to seek approval for the issuance of up to 4,642,632 shares of common stock. This issuance is in connection with a May 2026 licensing transaction for Ascendant-221 and a related private placement that generated approximately $30 million in gross proceeds. Shareholders will also vote on the Cue Biopharma, Inc. 2026 Stock Incentive Plan. The potential share issuance represents 142% of the company's outstanding common stock, necessitating stockholder approval under Nasdaq Listing Rules.
Key Highlights
- Special Meeting on June 1, 2026, to approve share issuance and 2026 Stock Incentive Plan.
- Approval sought for issuance of up to 4,642,632 common shares upon warrant exercise.
- Share issuance is for a licensing transaction and related private placement.
- Licensing deal includes $15.0 million upfront and up to $676.5 million in potential milestones.
- Private placement raised approximately $30 million gross proceeds.
- Total potential shares from warrants represent 142% of outstanding common stock.
- Record date for voting at the Special Meeting is May 8, 2026.
Price Impact
More from CUE